Inclusion body myositis (IBM) is an inflammatory myopathy causing proximal and distal muscle weakness. IBM’s cause remains ...
The following is a summary of “A systematic review and meta-analysis of the response to placebo in clinical trials of ...
US-based biotech Abcuro has raised $200m to advance the development of its monoclonal antibody ulviprubart in the rare muscle disease called inclusion body myositis (IBM). The funding round ...
New research examining the skeletal muscle cells of patients with inclusion body myositis (IBM) has revealed that the nucleic acid-binding protein TDP-43, which is normally restricted to the ...
Remind Magazine on MSN20d
Peter Frampton Officially Has a Service Dog Just in Time for His 2025 TourFrampton announced in 2019 that he was diagnosed with inclusion body myositis (IBM). According to Johns Hopkins Medicine, IBM ...
"IBM is a tremendously debilitating disease, which drastically and irreversibly reduces quality of life," commented Paula Eichenbrenner, executive director of The Myositis Association. "Exercise ...
1 Centro Hospitalar de Entre o Douro e Vouga – Physical and Rehabilitation Medicine Department – Santa Maria da Feira, Portugal 2 Physical and Rehabilitation Medicine – Portugal Myositis ossificans ...
Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback